Clinical Trial Update: A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Org 3236 (etonogestrel) tablets in men with urinary symptoms suggestive of benign prostatic hyperplasia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Org 3236 (Etonogestrel) Tablets (etonogestrel)

Snippet

Sponsor: Organon and Co | Conditions: Benign Prostatic Hyperplasia (BPH) | Phase 2 | Status: TERMINATED